Cocaine embryofetopathy
diseaseOn this page
Also known as cocaine antenatal exposurecocaine fetopathyfetal cocaine syndromefoetal cocaine syndromeprenatal cocaine exposure
Summary
Cocaine embryofetopathy (MONDO:0016007) is a disease. A subtype of toxic or drug-related embryofetopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide)
- Phenotypes (HPO): 8
Clinical features
Signs & symptoms
Clinical features (HPO)
8 HPO clinical features (Orphanet curated; top 8 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001276 | Hypertonia | Very frequent (80-99%) |
| HP:0001347 | Hyperreflexia | Very frequent (80-99%) |
| HP:0000079 | Abnormality of the urinary system | Occasional (5-29%) |
| HP:0001626 | Abnormality of the cardiovascular system | Occasional (5-29%) |
| HP:0002084 | Encephalocele | Occasional (5-29%) |
| HP:0009882 | Short distal phalanx of finger | Occasional (5-29%) |
| HP:0011100 | Intestinal atresia | Occasional (5-29%) |
| HP:0100657 | Celosomia | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cocaine embryofetopathy |
| Mondo ID | MONDO:0016007 |
| Orphanet | 1911 |
| ICD-11 | 1604796846 |
| SNOMED CT | 254250002 |
| UMLS | C0432371 |
| MedGen | 140937 |
| Is cancer (heuristic) | no |
Also known as: cocaine antenatal exposure · cocaine fetopathy · fetal cocaine syndrome · foetal cocaine syndrome · prenatal cocaine exposure
Disease family
Classification path: disease › human disease › disease by developmental or physiological process › disorder of development or morphogenesis › developmental defect during embryogenesis › toxic or drug-related embryofetopathy › cocaine embryofetopathy
Related subtypes (21): fetal iodine syndrome, fetal valproate syndrome, aminopterin/methotrexate embryofetopathy, indomethacin embryofetopathy, fetal hydantoin syndrome, fetal trimethadione syndrome, vitamin K-antagonist embryofetopathy, fetal alcohol syndrome, diethylstilbestrol syndrome, fetal methylmercury syndrome, fetal minoxidil syndrome, phenobarbital embryopathy, toluene embryopathy, methimazole embryofetopathy, isotretinoin syndrome, mycophenolate mofetil embryopathy, thalidomide embryopathy, fetal carbamazepine syndrome, acitretin/etretinate embryopathy, fetal phenothiazine syndrome, propylthiouracil embryofetopathy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.